Clinical Trial Search

Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score

Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities

Primary: Clot Specimen Histology — 373; 12 Count of specimen

Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants

Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants

Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale

Primary: All-cause Mortality at 1 Year (Percentage of Patients With Modified Rankin Scale (mRS) Score =6) — 11.1; 12.2 Percentage of Participants — p=0.183

Primary: Number of Participants Assessed for Revascularization With mTICI Grades 2b-3 — 724 Participants

Primary: Proportion of Subjects Whose Fugl-Meyer Motor Total Score (FMMS) Improved by ≥ 10 Points at Month 6 From Baseline — 7; 9; 7; 46 Participants — p=0.6743

Primary: Change in Corticomotor Excitability — 0.38; 0.37; 0.41; 0.37 millivolt (mV)

Primary: Number of Participants Needing ICU Care/Interventions Within the First 24 Hours of IV tPA Administration — 0 Participants

Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants

Primary: All-cause Mortality During Hospitalization of Acute Ischemic Stroke (AIS) Patients — 2.6; 0.8 Percentage of participants

Primary: Percent Change in Cerebral Blood Flow (CBF) — 0; 25 percentage increase in CBF

Primary: Change in Behavioral Intent to Call 911 — 2.1; 0.4 units on a scale

Primary: Myelin Basic Protein (MBP) Comparison Between the Two Groups Before and After Treatment — 0.42; 0.64; 0.41; 0.71 pg/ml

Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 1; 1; 0; 3 Participants

Primary: Evidence of Carotid Artery or Intracranial Artery Atherosclerosis Confirmed by Vascular Ultrasonography — 96; 1063; 826; 241 artery numbers

Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants

Primary: Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90 — 54.1; 41.5; 39.9 percentage of participants — p=0.086

Primary: Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours of Treatment Onset — 3; 2; 22; 99 participants — p=0.053

Primary: Utilization of Thrombolysis Among Ischemic Stroke and Transient Ischemic Attack (TIA) Patients — 4; 14 Percent of stroke and TIA patients

Primary: Time From Emergency Room Arrival to Initiation of Endovascular Stroke Therapy ("Door-to-groin" Time) — 100; 88 minutes

Primary: Frequency of Symptomatic Hemorrhagic Transformation Safety of iv Rt-PA in Wake up Stroke Patients — 0 cases.

Primary: Changes in Brain Activation — 48.5; -30 voxels

Primary: Feasibility and Tolerability of External Counterpulsation — 12; 9 participants

Primary: Blood Pressure and Heart Rates;

Primary: Technical Device Success by as Assessed by the Percentage of Participants Which Established at Least TIMI 2 Flow Upon Deployment of the System Across the Occlusion and…

Primary: Shift in Modified Rankin Scale (mRS) — 1; 1 score on a scale — p=0.71